PharmaMar obtains positive results on a drug against Covid-19

Crisis in Venezuela: the Nabarima oil tanker, full of crude, remains listed with several meters of its waterline underwater

Save 1.3 million barrels of oil. The environmental disaster would be gigantic if they spilled into the sea. But his case remains...

This has been the second Trump-Biden debate

With a very different tone from the sultry show of the first face to face, Donald Trump Y Joe Biden they were measured...

Truths and lies told in the last Trump versus Biden debate

PANDEMIC COVID-19 Evoking the new coronavirus, Donald Trump said that "we expected 2.2 million deaths, according to a model (of the epidemic). We...

Economic activity suffers again in Europe in the face of the second wave of the virus

Leading indicators point to a “risk of double recession” in the Old Continent, although the relapse would be less than in springThe second wave...

North Korea warns of yellow cloud of dust in China that could spread dangerous viruses

The streets of the Pyongyang capital were almost empty on Thursday, according to authorities. The state-controlled television station KCTV warned on Wednesday during the...

The biotech PharmaMar has announced that its APLICOV-PC clinical trial with Aplidin® (plitidepsin) for the treatment of adult patients with COVID-19 requiring hospital admission has met the primary safety and secondary efficacy objectives.

After the announcement, the company has skyrocketed on the stock market and around 10 am it was the one that rose the most on the IBEX-35, 11.06%%, to 144.6 euros per share. As PharmaMar explains in a note sent to the CNMV, the study has evaluated three cohorts of patients with three different dose levels of plitidepsin (1.5mg – 2.0mg – 2.5mg), administered for three consecutive days.

The viral load of the patients has been assessed at the start of treatment and on days 4, 7, 15 and 30 thereafter, and the study has shown a “remarkable reduction” of it between days 4 and 7 after the start of treatment, so that the mean reduction in viral load on day 7 was 50%, and 70% on day 15. More than 90% of the patients included in the trial had initially medium or high viral loads.

He 80.7% of the patients have been discharged from hospital on or before the 15th day of hospitalization, and 38.2%, before the 8th, explains the note, which recalls that according to the protocol, they must be hospitalized for a minimum of 7 days.



Related Articles